Line Plot from Scientific Research

Median (25–75%) serum hs-CRP concentrations in the placebo and three clazakizumab dose groups from baseline to week 24. The number of patients at weeks 0, 12 and 24, respectively, are placebo: 30, 26 and 10; clazakizumab 2.5 mg: 31, 24 and 13; clazakizumab 5 mg: 31, 26 and 10; clazakizumab 10 mg: 31, 25 and 10.

DOI